2. Search Result
Search Result
Results for "

(R)-( )-Warfarin

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128720
    Diethyl oxalpropionate

    		Endogenous Metabolite Metabolic Disease
    Diethyl oxalpropionate is an intermediate for poly((R,S)-3,3-dimethylmalic acid) (PDMMLA) derivative synthesis. PDMMLA derivative can be used in synthesis of nanoparticles and study of warfarin encapsulation and controlled release .
    Diethyl oxalpropionate
  • HY-W015998S
    (R)-(+)-Warfarin-d5

    		Isotope-Labeled Compounds Others
    (R)-(+)-Warfarin-d5 is deuterium labeled (R)-(+)-Warfarin.
    (R)-(+)-Warfarin-d5
  • HY-W015998
    (R)-(+)-Warfarin

    		Biochemical Assay Reagents Others
    (R)-(+)-Warfarin is a biochemical assay reagent.
    (R)-(+)-Warfarin
  • HY-121814A
    (R)-Acenocoumarol

    (R)-Acenocoumarin; (R)-Nicoumalone

    		 Others Others
    (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting oral anticoagulant that, like warfarin, works by inhibiting vitamin K epoxide reductase. In vitro evaluations have shown that (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a higher intrinsic anticoagulant potency than warfarin and phenprocoumon. (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a single chiral center that produces two different enantiomeric forms. (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a longer plasma elimination half-life (6.6 hours) and a slower plasma clearance rate (1.9 L/hour) compared to the (S)-enantiomer (1.8 hours, 28.5 L/hour). (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a more potent anticoagulant in vivo than the (S)-enantiomer.
    (R)-Acenocoumarol
  • HY-121535
    Levosemotiadil

    		Others Others
    Levosemotiadil, an S-isomer of semotiadil, exhibits stronger binding affinity to human serum albumin (HSA) compared to its R-isomer counterpart. This study utilized high-performance frontal analysis (HPFA) to demonstrate that levosemotiadil binds approximately three times more strongly to HSA than semotiadil. The binding parameters were evaluated using Scatchard analysis, revealing specific interactions with the diazepam binding site on HSA. The presence of diazepam decreased the binding affinity of both enantiomers, while warfarin did not alter their binding characteristics. These findings highlight levosemotiadil's potential as a Ca- and Na-channel blocker with significant binding preferences for HSA, crucial for understanding its pharmacokinetics and therapeutic effects .
    Levosemotiadil

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: